ILC Therapeutics™ Ltd (ILC) is pioneering a new class of interferon medicines called Hybrid Interferons. These take features of natural interferon subtypes and combine them into one new Hybrid Interferon molecule. These new molecules are designed to deliver enhanced efficacy and improved safety over a range of high value therapeutic areas creating life transforming outcomes for patients.

 

True platform technology

 

ILC builds design engineered patentable human interferon hybrids using DNA Bio-Brick Technology. This technology provides the opportunity to design and assess multiple novel Hybrid Interferons across different therapeutic areas with a series of immunology drug assets. The breadth of opportunity will enable both in-house pipeline and multiple 3rd party collaborations.

 

Lead candidate formulated for respiratory viral infections (RVI’s)

 

ILC’s lead candidate is called Alfacyte a wide spectrum anti-viral and is being developed for RVI’s as the first indication. These infections pose a major and growing global healthcare threat including COVID-19 (SARS-CoV-2) and beyond. Alfacyte has encouraging in-vitro data underpinning a breakthrough antiviral profile, suggesting enhanced efficacy and improved safety over current interferon therapies. Alfacyte is poised to commence Pre-Clinical studies leading to an MHRA regulated Clinical trial.

 

Building a pipeline beyond our lead candidate

 

With an active pipeline of Hybrids this provides the exciting opportunity of addressing major unmet medical needs. Opportunities exist to exploit the technology platform to make a significant impact in other areas of Virology such as Influenza, HIV, Hepatitis and many other major viral pathogens. The Hybrid Interferon platform will also target multiple high value therapeutic areas including Oncology, Dermatology, Inflammatory Lung Diseases and Crohn’s Disease.

 

Robust IP estate

 

The intellectual property is wholly owned by ILC with a patented portfolio of 9 families and growing. Patents cover Composition of Matter, DNA sequences and wide geography. Freedom to Operate reports cleared for Antiviral and Dermatology applications with others ongoing in other therapeutic areas.

 

A dynamic team and robust business model

 

 

A globally experienced and successful team at executive and Board level. Based in BioCity outside Glasgow in Scotland with outreach in London. Strong University links with St Andrews, Edinburgh, and Strathclyde. The ILC business model is focused on taking lead assets through Phase 2 clinical trials then partnering or out-licensing them to global pharmaceutical companies for further development, registration and eventual commercialisation.

 

 


Why Choose Us?

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed eget lacus quis velit viverra iaculis. Interdum et malesuada fames ac ante ipsum primis in faucibus. Vestibulum maximus ipsum ex. Curabitur elementum luctus augue, quis eleifend tortor feugiat vel. Maecenas maximus, ipsum et laoreet congue, diam massa aliquam libero, at pellentesque orci ipsum et velit. Quisque condimentum fermentum tellus at elementum. Morbi in dignissim sapien. Pellentesque interdum sem diam, in mattis lectus hendrerit vel. Nullam nibh diam, fringilla eget ultricies eget, porta eget sem. 

 

Quisque condimentum fermentum tellus at elementum. Morbi in dignissim sapien. Pellentesque interdum sem diam, in mattis lectus hendrerit vel. Nullam nibh diam, fringilla eget ultricies eget, porta eget sem. Praesent vulputate vestibulum felis, viverra interdum diam volutpat non